Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602727 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT05602727 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 99 participants.
The verdict
NCT05602727, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
Interventions
- DRUG Placebo
- DRUG MK-1942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2022-12-02 |
| Est. Completion | 2023-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602727
The ClinicalTrials.gov registry entry for NCT05602727 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05602727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05602727 about?
NCT05602727 is a clinical study titled "Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)". The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
What is the current status of trial NCT05602727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2022-12-02. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT05602727?
The interventions under investigation include: Placebo (DRUG), MK-1942 (DRUG).
Who is sponsoring clinical trial NCT05602727?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.